Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune escape mechanisms as a guide for cancer immunotherapy.

Literature DB >> 25501578

Immune escape mechanisms as a guide for cancer immunotherapy.

Abstract

Immunotherapy has demonstrated impressive outcomes for some patients with cancer. However, selecting patients who are most likely to respond to immunotherapy remains a clinical challenge. Here, we discuss immune escape mechanisms exploited by cancer and present strategies for applying this knowledge to improving the efficacy of cancer immunotherapy. ©2014 American Association for Cancer Research.

Entities: Chemical Disease Gene Species

Mesh：

Year: 2014 PMID： 25501578 PMCID： PMC4334715 DOI： 10.1158/1078-0432.CCR-14-1860

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

42 in total

Review 1. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors: Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal: Nat Rev Cancer Date: 2014-02 Impact factor: 60.716

2. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors: Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal: Neoplasia Date: 2014-01 Impact factor: 5.715

3. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Authors: Steven L Highfill; Yongzhi Cui; Amber J Giles; Jillian P Smith; Hua Zhang; Elizabeth Morse; Rosandra N Kaplan; Crystal L Mackall
Journal: Sci Transl Med Date: 2014-05-21 Impact factor: 17.956

4. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors: Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal: Clin Cancer Res Date: 2014-04-08 Impact factor: 12.531

5. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors: Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal: Science Date: 2014-05-09 Impact factor: 47.728

6. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

Authors: Nienke van Rooij; Marit M van Buuren; Daisy Philips; Arno Velds; Mireille Toebes; Bianca Heemskerk; Laura J A van Dijk; Sam Behjati; Henk Hilkmann; Dris El Atmioui; Marja Nieuwland; Michael R Stratton; Ron M Kerkhoven; Can Kesmir; John B Haanen; Pia Kvistborg; Ton N Schumacher
Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544

Review 7. Innate and adaptive immune cells in the tumor microenvironment.

Authors: Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal: Nat Immunol Date: 2013-10 Impact factor: 25.606

8. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

Authors: Stefani Spranger; Robbert M Spaapen; Yuanyuan Zha; Jason Williams; Yuru Meng; Thanh T Ha; Thomas F Gajewski
Journal: Sci Transl Med Date: 2013-08-28 Impact factor: 17.956

9. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

Authors: Jeffrey S Weber; Ragini Reiney Kudchadkar; Bin Yu; Donna Gallenstein; Christine E Horak; H David Inzunza; Xiuhua Zhao; Alberto J Martinez; Wenshi Wang; Geoffrey Gibney; Jodi Kroeger; Cabell Eysmans; Amod A Sarnaik; Y Ann Chen
Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544

10. VISTA Regulates the Development of Protective Antitumor Immunity.

Authors: Isabelle Le Mercier; Wenna Chen; Janet L Lines; Maria Day; Jiannan Li; Petra Sergent; Randolph J Noelle; Li Wang
Journal: Cancer Res Date: 2014-04-01 Impact factor: 12.701

311 in total

1. Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade.

Authors: Bo Ryeong Lee; Sehyun Chae; Jihyun Moon; Myeong Joon Kim; Hankyu Lee; Hyuk Wan Ko; Byoung Chul Cho; Hyo Sup Shim; Daehee Hwang; Hye Ryun Kim; Sang-Jun Ha
Journal: JCI Insight Date: 2020-07-23

Review 2. Present and future of cancer immunotherapy: A tumor microenvironmental perspective.

Authors: Yu Yu; Jiuwei Cui
Journal: Oncol Lett Date: 2018-07-26 Impact factor: 2.967

Review 3. Role of miRNAs in immune responses and immunotherapy in cancer.

Authors: Maria Angelica Cortez; Simone Anfossi; Rishab Ramapriyan; Hari Menon; Semra Cemre Atalar; Maureen Aliru; James Welsh; George A Calin
Journal: Genes Chromosomes Cancer Date: 2019-04 Impact factor: 5.006

Review 4. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors: Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal: Target Oncol Date: 2018-06 Impact factor: 4.493

Review 5. Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors: Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal: Nat Rev Clin Oncol Date: 2020-02-17 Impact factor: 66.675

6. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors: Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal: J Clin Invest Date: 2019-01-14 Impact factor: 14.808